Vendor, Carlsbad, CA
Lumos Diagnostics, Inc.
UEI CRKMAE3F8ZJ1, CAGE 82T59
1 award and $9,183,030 obligated between September 26, 2024 and August 27, 2025, 100% under full and open competition, against 1.0 offers on average where reported. 8 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $9,183,030 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $9,183,030 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00051Definitive Contract, September 26, 2024, Full and Open Competition, 1 offersSolicitation | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Execution of the Clinical Method Comparison Study and Regulatory Submission Required to Be Granted Clia-Waiver from the FDA for Febridx RespNAICS 541714, PSC AN42 | $9,183,030 |
- Places of performance
- California
- Product and service codes
- AN42 Health R&D Services; Health Care - Other; Applied Research
- Transactions
- 3 across 1 awards